However, it has been documented that in patients with advanced or unresectable metastatic paraganglioma, radiotherapy is effective in improving symptoms and controlling tumor growth, and higher radiation doses are associated with lower tumor recurrence.[13] In addition, patients with succinate dehydrogenase (SDH)-positive paragangliomas can achieve partial remission after treatment with tyrosine kinase inhibitors[14]; Sesti et al[15] reported that the multitargeted RTK inhibitor Sunitinib may be a viable treatment option for patients with inoperable paragangliomas. The gene discussed is SDHB; the disease is paraganglioma.